http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011144156-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9baf3defa9dc998356da178a79d4920 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec7aa9366c4867ba95ac5cd4fbbaec25 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-38 |
| filingDate | 2009-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8a1b1407eda973af1a5eefe43684e14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e81ead5eea87269c8429eddb2ce484c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b1056d923e7df0f32b20a0a8e54fcba |
| publicationDate | 2011-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2011144156-A1 |
| titleOfInvention | A3 adenosine receptor allosteric modulators |
| abstract | Provided are 2,4-disubstituted quinoline derivatives that are A3 adenosine receptor modulators (A 3 RM), for use in the treatment of a condition which is treatable by adenosine, an A 3 adenosine receptor (A 3 AR) agonist, or an A 3 adenosine receptor antagonist. The 2,4-disubstituted quinoline derivatives can be used in the treatment of a condition treatable by an adenosine or an A 3 AR agonist, by enhancing activity of a protein (by binding of said 2,4-disubstituted quinoline derivative to the A 3 AR). Some conditions treatable by the 2,4-disubstituted quinoline derivative when used for enhancing activity include, malignancy, an immuno-compromised affliction, high intraocular pressure, or a condition associated with high intraocular pressure. Further provided is a method for treatment of a subject having a condition treatable by adenosine, an A 3 AR agonist, or an A 3 AR antagonist making use of the defined 2,4-disubstituted quinoline derivative (s), and pharmaceutical composition and comprising said derivative and a kit comprising the derivative and instructions for use thereof. One specific 2,4-disubstituted quinoline derivative includes N-{2-[(3,4-dichlorophenyl)amino]quinolin-4-yl}cyclohexanecarboxamide. The 2,4-disubstituted quinoline derivatives can be formulated in a form suitable for oral administration. |
| priorityDate | 2008-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 390.